Streszczenie
4/2025
vol. 100
Artykuł oryginalny
Therapy with selumetinib in children with neurofibromatosis type 1 in Poland – clinical experience of the first year of the national program
- Department of Pediatric Hematology and Oncology, Collegium Medicum Nicolaus Copernicus University Toruń, Jurasz University Hospital, Bydgoszcz, Poland
- Department of Pediatric Hematology and Oncology, Clinical Transplantology and Pediatrics; Medical University of Warsaw, Warszawa, Poland
- Department of Pediatrics, Oncology and Hematology, Medical University of Łódź, Łódź, Poland
- Department of Pediatric Oncology and Hematology, Institute of Pediatrics, Jagiellonian University Medical College, Kraków, Poland
- Department of Oncology and Surgical Oncology for Children and Youth, Institute of Mother and Child, Warszawa, Poland
- Department of Oncology, Hematology and Chemotherapy, Division of Pediatrics, Medical University of Silesia, Upper Silesian Child Health Centre, Katowice, Poland
- Department of Pediatrics and Hematology and Oncology, Provincial Children’s Hospital, Olsztyn, Poland
- Department of Pediatric Hematology and Oncology and Transplantology, Medical University of Lublin, Lublin, Poland
- Department of Pediatric Hematology/Oncology and BMT, Medical University of Wrocław, Wrocław, Poland
- Department of Pediatrics, Institute of Medical Sciences, Collegium Medicum, University of Rzeszów, Rzeszów, Poland
- Department of Pediatrics, Hematology and Oncology, Medical University of Gdańsk, Gdańsk, Poland
- Department of Pediatric Oncology and Hematology, Children’s Hospital in Kielce, Kielce, Poland
- Department of Pediatric Oncology, Hematology and Transplantology, Poznań University of Medical Sciences, Poznań, Poland
Pediatr Pol 2025; 100 (4): 328-331
Data publikacji online: 2025/11/20
Zintergrowane z
